Navigation Links
Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint

mon adverse events among patients receiving Viread with other antiretroviral agents in a pivotal clinical study (Study 903) were mild to moderate gastrointestinal events and dizziness. Moderate to severe adverse events occurring in more than 5 percent of patients receiving Viread included rash (rash, pruritis, maculopapular rash, urticaria, vesiculobullous rash and pustular rash), headache, pain, diarrhea, depression, back pain, fever, nausea, abdominal pain, asthenia (weakness) and anxiety. In another pivotal study (Study 907), less than 1 percent of patients discontinued participation because of gastrointestinal events.

It is important for patients to be aware that anti-HIV medicines including Viread do not cure HIV infection or AIDS and do not reduce the risk of transmitting HIV to others. Full prescribing information is available at www.GileadHIV.com.

The parent compound of Viread was discovered through a collaborative research effort between Dr. Antonin Holy, Institute for Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic (IOCB) in Prague and Dr. Erik DeClercq, Rega Institute for Medical Research, Katholic University in Leuven, Belgium.

About Hepsera

Hepsera, a nucleotide analogue for the treatment of chronic hepatitis B, works by inhibiting HBV DNA polymerase, an enzyme involved in the replication of the virus in the body.

In the United States, Hepsera is indicated for the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.

The adverse reactions considered at least possibly related to treatment reported in 3 percent or greater of patients in the first 48 weeks in Hepsera pivotal clinical studies were asthenia, headache, abdominal pain, nausea, flatulence, diarrhea and dyspepsia. With extended treatment, mild to moderate increases in serum cre
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
4. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
5. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
6. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
10. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
Post Your Comments:
(Date:9/22/2014)... NORTH CHICAGO, Ill. , Sept. 22, 2014 ... that data from several clinical studies evaluating potential ... be presented at the upcoming 2014 European Society ... in Madrid, Spain . Data ... study evaluating the safety and efficacy of veliparib ...
(Date:9/22/2014)... , Sept. 22, 2014 Arena Pharmaceuticals, Inc. (NASDAQ: ... scheduled to present a corporate overview and update at ... September 26, 2014, at 11:30 a.m. Eastern Time (8:30 ... New York City . ... available under the investor relations section of Arena,s website ...
(Date:9/22/2014)... , September 22, 2014 ... "Cell Line Development Market by Product (Equipment, Media and ... Tissue Engineering & Regenerative medicine, Toxicity Testing, Research, ... 2019", published by MarketsandMarkets, analyzes and studies the ... Browse 114 market data tables and ...
Breaking Medicine Technology:AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 2Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 3Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4
(Date:9/22/2014)... Researchers have found that environment has a much ... a severe, often painful food allergy that renders ... foods. , Eosinophils are normal cellular components ... too many eosinophils they can cause a variety ... inflammation and resulting tissue damage, often in the ...
(Date:9/22/2014)... surprise, it turned out to be an old acquaintance: ... has hitherto always been considered an anchor protein. The ... , Essential: importing enzymes into peroxisome ... degradation of long-chain fatty acids and cellular toxins. In ... enzymes have to be imported into the peroxisomes first. ...
(Date:9/22/2014)... Cancer Science Institute of Singapore (CSI Singapore) at ... an increase in a gene known as Leo1 ... acute myelogenous leukaemia (AML), increasing the incidence of ... Wee Joo, Deputy Director and Senior Principal Investigator ... University Cancer Institute, Singapore, the scientists discovered that ...
(Date:9/22/2014)... Texas (PRWEB) September 22, 2014 ... and treatment, will work with companies to help employees ... the development of diabetes as part of a collaboration ... Diabetes @ Work initiative. , PreDiabetes Centers Medical ... Department of Transportation in Austin on Tuesday, October 21st ...
(Date:9/22/2014)... 22, 2014 The invitation only ... attended by 60 industry executives and thought leaders ... International, GoodLife, Retro Fitness, and Xsport Fitness. Also ... retention and marketing agencies and private equity investors ... gym members. , The Summit highlighted best practices ...
Breaking Medicine News(10 mins):Health News:Environment plays bigger role than genetics in food allergic disease eosinophilic esophagitis 2Health News:The accelerator of molecular motors 2Health News:Singapore researchers discover a gene that increases incidence of AML 2Health News:PreDiabetes Centers to Offer Diabetes Screening at Several Companies Around Austin 2Health News:PreDiabetes Centers to Offer Diabetes Screening at Several Companies Around Austin 3Health News:Motionsoft Concludes Inaugural 2014 Technology Summit 2Health News:Motionsoft Concludes Inaugural 2014 Technology Summit 3
... chief of Renal Medicine and director of the Nephrology ... of medicine at Boston University School of Medicine (BUSM) ... Castle Connolly Medical Ltd. , The America,s Top Doctors ... a trusted and authoritative resource for identifying top doctors ...
... To improve the quality of the rapidly expanding array ... entered into a Memorandum of Understanding (MOU) with the ... for Biological Standards and Control (NIBSC) of the United ... plants or animals, rather than those created in a ...
... related to quality of marriage relationship, , , THURSDAY, Dec. ... poorer outcomes for women with breast cancer, a new ... in troubled marriages had higher levels of stress, less ... of illness than women who reported good marriages. ...
... men with chronic prostatitis, a painful disorder of the ... symptoms in recently diagnosed men who had not been ... trial sponsored by the National Institute of Diabetes and ... Institutes of Health (NIH). The study is to be ...
... Society has worked out new guidelines for the diagnosis ... Malignant melanoma is responsible for 90% of deaths from ... last 30 years and UV radiation is thought to ... , Claus Garbe of Tbingen University and his ...
... time with kids is one option to consider , , THURSDAY, ... be important considerations when you,re looking for children,s Christmas gifts, ... Philadelphia. , "Parents often feel like they have to ... chairman and professor of occupational therapy, said in a university ...
Cached Medicine News:Health News:Marital Distress May Affect Breast Cancer Recovery 2Health News:Common treatment for chronic prostatitis fails to reduce symptoms 2Health News:'Hot' Toys May Not Be the Best Present 2
... is a family of solutions that ... individuals inside hospitals, healthcare facilities, or ... The target tracking areas are networked ... of radio frequency identification (RFID) readers ...
Assetrac allows identification, location, and protection of your assets....
... The RoamAlert Integrity system builds ... ECO. All door controllers in the ... computer running a standard Windows® operating ... the use of a personal computer, ...
... uses RFID to gather patient ... departments such as surgical and ... updates of patient location to ... care events have occurred and ...
Medicine Products: